Besylate salt of a BTK inhibitor
The present invention provides a salt form, and compositions thereof, useful as an inhibitor of one or more protein kinases and which exhibits desirable characteristics for the same.
1. A solid form of Compound 2:
having one or more peaks in its PXRD selected from those at about 6.21, about 9.48, and about 13.29 degrees 2-theta.
2. The solid form according to claim 1 , having at least two peaks in its PXRD selected from those at about 6.21, about 9.48, and about 13.29 degrees 2-theta.
3. The solid form according to claim 1 , having a PXRD substantially similar to that depicted in FIG. 2 .
4. A solid form of Compound 2:
having one or more peaks in its PXRD selected from those at about 7.29, about 8.38, and about 11.12 degrees 2-theta.
5. The solid form according to claim 4 , having at least two peaks in its PXRD selected from those at about 7.29, about 8.38, and about 11.12 degrees 2-theta.
6. The solid form according to claim 4 , having a PXRD substantially similar to that depicted in FIG. 6 .
7. A composition comprising the solid form according to claim 1 and a pharmaceutically acceptable carrier or excipient.
8. A composition comprising the solid form according to claim 4 and a pharmaceutically acceptable carrier or excipient.
9. The solid form according to claim 1 , wherein said form is Form P1.
10. The solid form according to claim 1 , wherein said form is substantially free of amorphous Compound 2.
11. The solid form according to claim 1 , wherein said form is substantially free of impurities.
12. The solid form according to claim 4 , wherein said form is Form P22.
13. The solid form according to claim 4 , wherein said form is substantially free of amorphous Compound 2.
14. The solid form according to claim 4 , wherein said form is substantially free of impurities.